Skip to Main Content

Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors

Conditions

Addictive Behaviors | Alcohol Addiction | Mental Health & Behavioral Research

Phase I

What is the purpose of this trial?

The primary purpose of the study is to increase our knowledge of receptor function in the brains of people who are heavy drinkers and taking naltrexone (NTX), a medication that has been approved for the treatment of alcohol dependence. Receptors are special molecules in the brain to which other molecules (neurotransmitters) attach during the normal every-day workings of the brain. Drugs can bind to those receptor molecules as well. Recent evidence suggests that kappa opioid receptors (KOR's) may play an important role in alcohol drinking behavior. This study will try to determine if naltrexone's ability to attach to these receptors is related to its effectiveness. We will use PET (positron emission tomography) for this study. PET is a type of imaging device found in nuclear medicine. It is used for tracking the presence of injected radioactive materials in the body.

  • Trial with
    National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • Start Date
    07/23/2013
  • End Date
    02/18/2016
Trial Image

For more information about this study, contact:

Mark Dias

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/24/2019
  • Study HIC
    #1011007710